To Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU
Lyon, France and Yongin, Republic of Korea – August 27, 2026 – Osivax, a clinical-stage biopharmaceutical company developing differentiated influenza vaccines designed to generate broad-spectrum immune responses, and GC Biopharma, a leading South Korean biopharmaceutical company with extensive experience in vaccines and plasma-derived products, today announced a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine candidate designed to provide broader and more durable protection against a wide range of influenza strains.
Under the agreement, the companies will develop the combination of OVX836, Osivax’s broad-spectrum influenza A vaccine candidate targeting the highly conserved nucleoprotein (NP), with GC FLU, GC Biopharma’s standard-dose, WHO-prequalified, inactivated seasonal influenza vaccine, in a single injection. The combination is expected to leverage complementary immune mechanisms to provide higher and broader protection against circulating and emerging influenza strains. OVX836 is designed to induce T-cell responses against the highly conserved NP antigen, while GC FLU provides antibody responses against the well-known Hemagglutinin (HA) surface antigen.
